108 related articles for article (PubMed ID: 520097)
1. Chronochemotherapy: L 1210 leukemia and beyond.
Halberg F; Nelson W; Cornélissen G; Haus E; Scheving LE; Good RA
Chronobiologia; 1979; 6(3):203-11. PubMed ID: 520097
[TBL] [Abstract][Full Text] [Related]
2. Chronochemotherapy of L1210 leukemic mice with cytosine arabinoside or cyclophosphamide.
Rose WC; Trader MW; Laster WR; Schabel FM
Cancer Treat Rep; 1978 Sep; 62(9):1337-49. PubMed ID: 688277
[No Abstract] [Full Text] [Related]
3. Survival and cure of leukemic mice after circadian optimization of treatment with cyclophosphamide and 1-beta-D-arabinofuranosylcytosine.
Scheving LE; Burns ER; Pauly JE; Halberg F; Haus E
Cancer Res; 1977 Oct; 37(10):3648-55. PubMed ID: 908013
[TBL] [Abstract][Full Text] [Related]
4. Combined chronochemotherapy of L1210 leukemic mice using 1-beta-D-arabinofuranosylcytosine, cyclophosphamide, vincristine, methylprednisolone and cis-diamminedichloroplatinum.
Scheving LE; Burns ER; Halberg F; Pauly JE
Chronobiologia; 1980; 7(1):33-40. PubMed ID: 7192203
[TBL] [Abstract][Full Text] [Related]
5. On methods for testing and achieving cancer chronotherapy.
Halberg F; Nelson W; Cornelissen G; Haus E; Scheving LE; Good RA
Cancer Treat Rep; 1979 Aug; 63(8):1428-30. PubMed ID: 476717
[No Abstract] [Full Text] [Related]
6. Circadian optimization of the treatment of L1210 leukemia with 1-beta-D-arabinofuranosylcytosine, cyclophosphamide, vincristine and methylprednisolone.
Burns ER; Scheving LE
Chronobiologia; 1980; 7(1):41-51. PubMed ID: 7438892
[No Abstract] [Full Text] [Related]
7. Circadian bioperiodic response of mice bearing advanced L1210 leukemia to combination therapy with adriamycin and cyclophosphamide.
Scheving LE; Burns ER; Pauly JE; Halberg F
Cancer Res; 1980 May; 40(5):1511-5. PubMed ID: 7370988
[No Abstract] [Full Text] [Related]
8. Single versus combination chemotherapy of L1210 leukemia.
Koza I; Balázová E; Ujházy V
Neoplasma; 1980; 27(6):691-6. PubMed ID: 7254424
[TBL] [Abstract][Full Text] [Related]
9. Combination chemotherapy in sequence for the treatment of L1210 leukemia.
Roberts D; Hilliard SL
Cancer Res; 1978 Aug; 38(8):2317-20. PubMed ID: 667827
[No Abstract] [Full Text] [Related]
10. Sequential chemotherapy with cyclophosphamide (NSC-26271) and cytosine arabinoside (NSC-63878) in mice with advanced leukemia L1210.
Hoffman GS; Kline I; Gang M; Tyrer DD; Goldin A; Mantel N; Venditti JM
Cancer Chemother Rep; 1969 Oct; 53(5):265-71. PubMed ID: 5377613
[No Abstract] [Full Text] [Related]
11. Effect of different doses of methotrexate (NSC-740), cytosine arabinoside (NSC-63878), and cyclophosphamide (NSC-26271) on drug resistance in mice with L1210 leukemia.
Schmid FA; Hutchison DJ
Cancer Chemother Rep; 1972 Aug; 56(4):473-81. PubMed ID: 5081590
[No Abstract] [Full Text] [Related]
12. [Modern aspects of using chronopharmacology in hematology. II. Biorhythms in drug effects].
Berger J; Mikeska J
Cas Lek Cesk; 1985 Sep; 124(38-39):1220-2. PubMed ID: 4053157
[No Abstract] [Full Text] [Related]
13. Adriamycin and cyclophosphamide in combination chemotherapy of L1210 leukemia.
Avery TL; Roberts D
Cancer Res; 1977 Mar; 37(3):678-83. PubMed ID: 837368
[TBL] [Abstract][Full Text] [Related]
14. Selective chemotherapy for advanced murine L 1210 leukemia by combination of 2' deoxycytidine and lethal doses of cytosine-arabinoside.
Buchman VM; Svet-Maoldavsky GJ; Lichinitser MR; Mkheidze DM
Biomedicine; 1977 Jul; 27(5):179-80. PubMed ID: 922116
[TBL] [Abstract][Full Text] [Related]
15. [Chronobiological aspects of experimental leukemia].
Ratte J; Haus E; Halberg F; Kühl JF; Shiotsuka R; Najarian JS
Union Med Can; 1974 Jul; 103(7):1201-7. PubMed ID: 4842174
[No Abstract] [Full Text] [Related]
16. Circadian dependence of host and tumor responses to cyclophosphamide in mice.
Cardoso SS; Avery T; Venditti JM; Goldin A
Eur J Cancer (1965); 1978 Sep; 14(9):949-54. PubMed ID: 710487
[No Abstract] [Full Text] [Related]
17. Combined therapy of L1210 leukemia with cyclophosphamide and lycurim.
Stoychkov JN; Milushev AS; Todorov DK
Neoplasma; 1980; 27(1):33-6. PubMed ID: 6892839
[TBL] [Abstract][Full Text] [Related]
18. Schedule-dependent synergism for the combination of 1-beta-D-arabinofuranosylcytosine and daunorubicin.
Edelstein M; Vietti T; Valeriote F
Cancer Res; 1974 Feb; 34(2):293-7. PubMed ID: 4810905
[No Abstract] [Full Text] [Related]
19. Close reproduction by different laboratories of characteristics of circadian rhythm in 1-beta-D-arabinofuranosylcytosine tolerance by mice.
Scheving LE; Haus E; Kühl JF; Pauly JE; Halberg F; Cardoso S
Cancer Res; 1976 Mar; 36(3):1133-7. PubMed ID: 1253172
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of antileukemic agents in advanced leukemia L1210 in mice. IX.
Kline I; Gang M; Tyrer DD; Venditti JM; Artis EW; Goldin A
Cancer Chemother Rep 2; 1971 Apr; 2(1):65-133. PubMed ID: 5565539
[No Abstract] [Full Text] [Related]
[Next] [New Search]
